Clinical Trials
79 trialsCT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Roswell Park Cancer Institute
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Oncovir, Inc.
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
ENSURE
Erasmus Medical Center
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
8479217
BerGenBio ASA
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
MESOVAX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
National Institutes of Health Clinical Center (CC)
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
A Study of SGN-CD228A in Advanced Solid Tumors
Seagen Inc.
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Bayer
CAMP1
Mabpro, a.s.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NVB Metro
Assistance Publique Hopitaux De Marseille
Dasatinib in Resectable Malignant Pleural Mesothelioma
M.D. Anderson Cancer Center
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Mayo Clinic
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Pembrolizumab + Defactinib In Pleural Mesothelioma
Dana-Farber Cancer Institute
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Aduro Biotech, Inc.
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Gene Therapy for Pleural Malignancies
University of Pennsylvania